Smith & Nephew

Q1 20: COVID-19 pain set to peak in Q2?

12/05/20 -"Smith & Nephew saw Q1 20 revenue decline by 7.6%, on an underlying basis – driven by broad-based weakness, as the COVID-19 outbreak hurt elective procedure volumes. With April revenue down 47%, ..."

PDF page sample
Pages
60
Language
English
Published on
12/05/20
Download
You may also be interested by these reports :
24/04/24
Getinge reported a mixed set of results, missing top-line estimates marginally but beating on profit and order intake. Investors cheered the latter, ...
23/04/24
We have factored the 2023 actual figures into our model ahead of the availability of the annual report and more detailed information. The difference ...
22/04/24
Sartorius Stedim reported softer-than-expected Q1 24 numbers, missing the consensus by 5.7%/3.4% on the top line/bottom line, respectively. The ...
22/04/24
Sartorius reported softer-than-expected Q1 24 numbers, missing the consensus by 5.4% on the top line, but beating (+2.4%) on the bottom line. The ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO